Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at ...

Immutep shares rocket after a fresh FDA win The post Why this ASX biotech stock just rocketed 89% today appeared first on The ...

What started as a conversation between friends over drinks has grown into a South African biotech breakthrough that could ...

The latest trial milestone sends this ASX biotech stock higher today. The post This ASX biotech stock just jumped again as its lead drug trial moves ahead appeared first on The Motley Fool Australia.

Dr. Houman Hemmati, an ophthalmologist critical of the government’s Covid vaccine response, is the front-runner for the role ...

Houman Hemmati, a board-certified ophthalmologist, biotech executive and frequent Fox News guest, is a candidate to become ...

Gossamer Bio is picking up the pieces after failing to bring its only late-stage drug to market. The local biotech plans to ...

Roanoke City's Director of Economic Development calls the five year journey from visioning to securing the funds and then ...

Revolution Medicines (RVMD) is one of the best stocks on Wall Street today after breakthrough cancer pill results ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

Replimune’s CEO Sushil Patel has already warned that the biotech will need to cut staff and substantially scale back its U.S. manufacturing operations.